Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT04659369 is registered in ClinicalTrials.gov with Taizhou Mabtech Pharmaceutical Co.,Ltd as lead sponsor.

NCT NCT04659369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04659369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase
Phase 1
Overall status
Terminated
Start date
September 24, 2020
Completion date
October 16, 2023
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck